Beta thalassemia - a review
Thalassemia is a globin gene disorder that results in a diminished rate of synthesis of one or more of the globin chains. About 1.5% of the global population (80 to 90 million people) are carriers of beta Thalassemia. More than 200 mutations are described in beta thalassemia. However not all mutations are common in different ethnic groups. The only effective way to reduce burden of thalassemia is to prevent birth of homozygotes. Diagnosis of beta thalassemia can be done by fetal DNA analysis for molecular defects of beta thalassemia or by fetal blood analysis. Hematopoietic stem cell transplantation is the only available curative approach for Thalassemia. Many patients with thalassemia in underdeveloped nations die in childhood or adolescence. Programs that provide acceptable care, including transfusion of safe blood and supportive therapy including chelation must be established.
Journal of Pathology of Nepal; Vol.4,No. 8 (2014) 663-671
Copyright on any article published by Journal of Pathology of Nepal is retained by the author(s).
Authors grant Journal of Pathology of Nepal a license to publish the article and identify itself as the original publisher.
Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
All articles published in the Journal of Pathology are licensed under a Creative Commons Attribution 4.0 International License.
This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.